FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington,	D.C.	20549	

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								<u> </u>												
1. Name and Address of Reporting Person* <u>Wainer Andrea F</u>						2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]										Relationship eck all appli Directo	cable) or	g Per	10% Ov	vner
(Last) 100 ABI	(F BOTT PARI	•	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/02/2021									X Officer (give title below) Other (spe below) EXECUTIVE VICE PRESIDENT					
(Street)	T PARK IL	,	60064		4. If	4. If Amendment, Date of Original Filed (Month						(Month/Da	ay/Year)		Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)													1 01301	•			
		Tab	le I - No	n-Deriv	ative	e Se	curit	ies Ac	quire	d, D	isp	osed c	f, or E	ene	ficial	ly Owned	i			
1. Title of Security (Instr. 3) 2. Transic Date (Month/It				Execution Date,			Cod	Transaction Disposed Of (D) Code (Instr. 5)						5. Amount of Securities Beneficially Owned Following Reported		Form: Direct		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										e v		Amount	(A) or Pri		Price	Transac (Instr. 3	tion(s)			(111341.4)
Common shares without par value 09/0			09/02	2/2021	/2021		М			4,500 A		\$47	54,282			D				
Common	shares with	out par value	09/02/2021			М			5,000 A			\$38.4	59,282			D				
Common	shares with	out par value		09/02	2/2021	1			S			9,500) [) :	\$ <mark>127</mark> .	5 49	,782	2 D		
		T	able II -	Deriva (e.g., p												Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)		n of E		Expirat	6. Date Exercisa Expiration Date Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Ex Da	xpiration ate	Title	or Nu of	nount mber ares					
Option (right to buy) ⁽¹⁾	\$47	09/02/2021		ĺ	М			4,500	02/20/2	016	02/	/19/2025	Commo Shares	4,	500	\$0	38,226	5	D	
Option (right to	\$38.4	09/02/2021			M			5,000	02/19/2	:017	02/	/18/2026	Commo	₁ 5,	000	\$0	30,000)]	D	

Explanation of Responses:

1. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact 09/03/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.